Meta-analysis of placebo responses in metabolic dysfunction-associated steatohepatitis trials reveals modest natural resolution rates and low progression risk.
New meta-analysis shows how many patients improve on placebo for MASH
This systematic review and meta-analysis examined placebo outcomes in patients with metabolic dysfunction-associated steatohepatitis. The au…
This analysis of 6,880 patients reveals natural improvement rates in metabolic dysfunction-associated steatohepatitis when no active drug is…
Network meta-analysis suggests tirzepatide and surgery improve MASH resolution versus standard care in adults with obesity
Weight-loss drugs and surgery may clear fatty liver disease in adults with high BMI
This systematic review and network meta-analysis evaluates interventions for metabolic dysfunction-associated steatotic liver disease and st…
A new analysis suggests tirzepatide, semaglutide, and surgery might help resolve fatty liver disease without worsening scarring in adults wi…
Systematic review and meta-analysis evaluates ML and DL models for diagnosing MASH and fibrosis
AI models help doctors spot liver disease with high accuracy
This systematic review and meta-analysis of 106 studies assessed machine learning (ML) and deep learning (DL) models for diagnosing metaboli…
New computer tools can diagnose fatty liver disease and scarring with impressive accuracy. This review analyzed data from many studies to se…
Pathophysiological review explores platelet activity and antiplatelet agents in metabolic dysfunction-associated steatohepatitis and steatotic liver disease.
New Role for Blood Cells in Fatty Liver Disease Could Change Treatment
This pathophysiological review examines the role of platelet activity and antiplatelet agents in metabolic dysfunction-associated steatohepa…
Understanding how blood cells affect your liver could lead to new, targeted treatments for a dangerous liver condition.
Transcriptomic signature distinguishes MASL from MASH using neural network model
New Blood Test Could Spot Hidden Liver Damage Before It’s Too Late
This observational study combined transcriptomic and single-cell analysis with an artificial neural network to differentiate metabolic dysfu…
This research could finally give doctors a simple blood test to tell the difference between harmless fat buildup and dangerous liver scarrin…
Observational study links semaglutide dose and weight loss to lower liver disease risk.
Study links semaglutide use to lower risk of several liver conditions in patients with liver disease
This observational study from a real-world federated EHR network analyzed 6,734 patients with liver disease. It found associations between h…
Higher semaglutide doses and greater weight loss were linked to lower risks of steatohepatitis, alcoholic liver disease, and death in patien…
Perspective reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis
Could new drugs finally treat the liver scarring of MASH?
A perspective article reviews emerging antifibrotic therapies for metabolic dysfunction-associated steatohepatitis (MASH), including metabol…
New metabolic drugs and direct liver therapies offer fresh hope for reversing the scarring that leads to dangerous cirrhosis in MASH patient…